The presentation is a standard corporate update with no new data — this is a non-event for the stock. Monitor Q3 2026 for the Phase 2b LUMUS SLE readout and Q4 2026 for the psoriasis NDA filing as the next key catalysts. The cash runway into Q4 2027 suggests no near-term financing overhang.
Price Chart
Executive Summary
Alumis Inc. furnished an updated corporate investor presentation via an 8-K (Item 8.01), highlighting positive Phase 3 psoriasis data for envudeucitinib (leading PASI 100 responses) and key upcoming milestones: NDA filing for psoriasis in Q4 2026, Phase 2b SLE (LUMUS) topline data in Q3 2026, and A-005 Phase 2 Parkinson's initiation in 1H 2027. The filing is a routine corporate update with no new material financial data or clinical results beyond previously presented AAD data; it reinforces the pipeline narrative and upcoming catalysts without changing the risk/reward profile.
Key Facts
- Alumis posted an updated corporate deck on June 29, 2026, with no new financial or clinical data beyond Phase 3 ONWARD1/ONWARD2 AAD results
- Envudeucitinib Phase 3 showed leading PASI 100 skin clearance at Week 24 (41.0% ONWARD1, 39.5% ONWARD2) and statistically significant PASI 90 responses vs placebo and apremilast
- Cash position of $569.5M as of March 31, 2026, with runway into Q4 2027
- Key near-term milestones: NDA filing for envudeucitinib in plaque psoriasis (Q4 2026), Phase 2b LUMUS SLE topline results (Q3 2026), Phase 2 biomarker trial start for A-005 in Parkinson's (1H 2027)
- Lumus Phase 2b SLE trial fully enrolled (n=408), could enable accelerated regulatory pathway
Financial Impact
No new financial guidance or results provided; cash runway of $569.5M into Q4 2027
Risk Factors
- Phase 2b SLE (LUMUS) trial failure would remove a major pipeline catalyst and could materially reduce the stock's risk/reward profile
- Psoriasis NDA filing or FDA review delays could push commercialization timeline
- Pre-revenue clinical-stage biotech with no approved products — all value depends on clinical and regulatory execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078507 |
| Document: tm2619143d1_8k.htm | 0001104659-26-078507 |
| Document: 0001104659-26-078507-index-headers.html | 0001104659-26-078507 |
| Document: 0001104659-26-078507-index.html | 0001104659-26-078507 |
| Document: 0001104659-26-078507.txt | 0001104659-26-078507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | Insider Buy | $9.90 $9.18 | ▼ −7.27% | ▼ −8.13% | $6.51 (−34.24%) |
Sep 1, 2026 7w ago | 8-K | $9.47 $10.35 | ▲ +9.29% | ▲ +8.85% | $6.51 (−31.26%) |
Aug 15, 2026 10w ago | Institutional Cluster | $25.50 $24.88 | ▼ −2.43% | ▼ −1.76% | $6.51 (−74.47%) |
Aug 10, 2026 11w ago | 8-K | $25.37 $25.55 | ▲ +0.71% | ▲ +0.46% | $6.51 (−74.34%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.51 (−76.58%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.51 (−76.58%) |
Jun 29, 2026 17w ago | 8-K | $27.14 $28.14 | ▲ +3.68% | ▲ +2.91% | $6.51 (−76.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $20.90 $24.15 | ▲ +15.55% | ▲ +15.01% | $6.51 (−68.85%) |
May 18, 2026 23w ago | DEFA14A | $21.53 $22.04 | ▲ +2.39% | ▲ +1.35% | $6.51 (−69.76%) |
Mar 28, 2026 30w ago | Press Release | $20.21 $22.03 | ▲ +9.01% | ▲ +6.11% | $6.51 (−67.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers